Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis

Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2013-06, Vol.63 (6), p.998-1008
Hauptverfasser: Abdollah, Firas, Suardi, Nazareno, Cozzarini, Cesare, Gallina, Andrea, Capitanio, Umberto, Bianchi, Marco, Sun, Maxine, Fossati, Nicola, Passoni, Niccolò Maria, Fiorino, Claudio, Di Muzio, Nadia, Karakiewicz, Pierre I, Rigatti, Patrizio, Montorsi, Francesco, Briganti, Alberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1008
container_issue 6
container_start_page 998
container_title European urology
container_volume 63
creator Abdollah, Firas
Suardi, Nazareno
Cozzarini, Cesare
Gallina, Andrea
Capitanio, Umberto
Bianchi, Marco
Sun, Maxine
Fossati, Nicola
Passoni, Niccolò Maria
Fiorino, Claudio
Di Muzio, Nadia
Karakiewicz, Pierre I
Rigatti, Patrizio
Montorsi, Francesco
Briganti, Alberto
description Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP.
doi_str_mv 10.1016/j.eururo.2012.10.036
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1345513402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0302283812012675</els_id><sourcerecordid>1345513402</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</originalsourceid><addsrcrecordid>eNqFUsuqFDEUDKJ4x6t_IJKN4KbHPPo1LoRm8AUDVxxdh3Tn5JqxuzMm6YH-Az_b03fmKrhxkQSKqkpOVQh5ztmaM16-PqxhClPwa8G4QGjNZPmArHhdyawqSvaQrJhkIhO1rK_IkxgPjDFZbORjciUkF6Is8xX5tYceuuTGW5q-A705Jjfonm71aJzRCaj1gTbmMJ30mOgXbZxHXtDHmTY2QbiDOlR8Dj4mFHTJD_Od6h5ZzDoIb2hDd368zVA10P0UTu6EumbU_RxdfEoeWd1HeHY5r8m39---bj9mu5sPn7bNLuvyvEpZVTPB2tLktrXc4NqIVra8kGUnBectF3VdaFZVYO2myouilrayLZi65LmAXF6TV2ffY_A_J4hJDS520Pd6BD9FxSWKcGMCqfmZ2uEkMYBVx4DphFlxppYO1EGdO1BLBwuKHaDsxeWGqR3A_BHdh46ElxeCjhidDZiPi395leSSbRjy3p55gHmcHAQVOweYpXEBc1bGu_-95F-DrnfjUtcPmCEe_BQwfZxZRaGY2i__ZfkufDEpq0L-BhOHvOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1345513402</pqid></control><display><type>article</type><title>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Abdollah, Firas ; Suardi, Nazareno ; Cozzarini, Cesare ; Gallina, Andrea ; Capitanio, Umberto ; Bianchi, Marco ; Sun, Maxine ; Fossati, Nicola ; Passoni, Niccolò Maria ; Fiorino, Claudio ; Di Muzio, Nadia ; Karakiewicz, Pierre I ; Rigatti, Patrizio ; Montorsi, Francesco ; Briganti, Alberto</creator><creatorcontrib>Abdollah, Firas ; Suardi, Nazareno ; Cozzarini, Cesare ; Gallina, Andrea ; Capitanio, Umberto ; Bianchi, Marco ; Sun, Maxine ; Fossati, Nicola ; Passoni, Niccolò Maria ; Fiorino, Claudio ; Di Muzio, Nadia ; Karakiewicz, Pierre I ; Rigatti, Patrizio ; Montorsi, Francesco ; Briganti, Alberto</creatorcontrib><description>Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2012.10.036</identifier><identifier>PMID: 23122664</identifier><identifier>CODEN: EUURAV</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Adjuvant ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cohort Studies ; Combined Modality Therapy ; Disease-Free Survival ; Gynecology. Andrology. Obstetrics ; Humans ; Lymph Node Excision ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Grading ; Neoplasm recurrence ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Patient Selection ; Pelvis ; Proportional Hazards Models ; Prostatectomy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Prostatic neoplasms/surgery ; Radiotherapy ; Radiotherapy, Adjuvant ; Retrospective Studies ; Risk Assessment ; Risk factors ; Survival Analysis ; Treatment Outcome ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; Urology</subject><ispartof>European urology, 2013-06, Vol.63 (6), p.998-1008</ispartof><rights>European Association of Urology</rights><rights>2012 European Association of Urology</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2012 European Association of Urology. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</citedby><cites>FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.eururo.2012.10.036$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27313090$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23122664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdollah, Firas</creatorcontrib><creatorcontrib>Suardi, Nazareno</creatorcontrib><creatorcontrib>Cozzarini, Cesare</creatorcontrib><creatorcontrib>Gallina, Andrea</creatorcontrib><creatorcontrib>Capitanio, Umberto</creatorcontrib><creatorcontrib>Bianchi, Marco</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Fossati, Nicola</creatorcontrib><creatorcontrib>Passoni, Niccolò Maria</creatorcontrib><creatorcontrib>Fiorino, Claudio</creatorcontrib><creatorcontrib>Di Muzio, Nadia</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I</creatorcontrib><creatorcontrib>Rigatti, Patrizio</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><title>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP.</description><subject>Adjuvant</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Grading</subject><subject>Neoplasm recurrence</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Patient Selection</subject><subject>Pelvis</subject><subject>Proportional Hazards Models</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Prostatic neoplasms/surgery</subject><subject>Radiotherapy</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk factors</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>Urology</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuqFDEUDKJ4x6t_IJKN4KbHPPo1LoRm8AUDVxxdh3Tn5JqxuzMm6YH-Az_b03fmKrhxkQSKqkpOVQh5ztmaM16-PqxhClPwa8G4QGjNZPmArHhdyawqSvaQrJhkIhO1rK_IkxgPjDFZbORjciUkF6Is8xX5tYceuuTGW5q-A705Jjfonm71aJzRCaj1gTbmMJ30mOgXbZxHXtDHmTY2QbiDOlR8Dj4mFHTJD_Od6h5ZzDoIb2hDd368zVA10P0UTu6EumbU_RxdfEoeWd1HeHY5r8m39---bj9mu5sPn7bNLuvyvEpZVTPB2tLktrXc4NqIVra8kGUnBectF3VdaFZVYO2myouilrayLZi65LmAXF6TV2ffY_A_J4hJDS520Pd6BD9FxSWKcGMCqfmZ2uEkMYBVx4DphFlxppYO1EGdO1BLBwuKHaDsxeWGqR3A_BHdh46ElxeCjhidDZiPi395leSSbRjy3p55gHmcHAQVOweYpXEBc1bGu_-95F-DrnfjUtcPmCEe_BQwfZxZRaGY2i__ZfkufDEpq0L-BhOHvOA</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Abdollah, Firas</creator><creator>Suardi, Nazareno</creator><creator>Cozzarini, Cesare</creator><creator>Gallina, Andrea</creator><creator>Capitanio, Umberto</creator><creator>Bianchi, Marco</creator><creator>Sun, Maxine</creator><creator>Fossati, Nicola</creator><creator>Passoni, Niccolò Maria</creator><creator>Fiorino, Claudio</creator><creator>Di Muzio, Nadia</creator><creator>Karakiewicz, Pierre I</creator><creator>Rigatti, Patrizio</creator><creator>Montorsi, Francesco</creator><creator>Briganti, Alberto</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</title><author>Abdollah, Firas ; Suardi, Nazareno ; Cozzarini, Cesare ; Gallina, Andrea ; Capitanio, Umberto ; Bianchi, Marco ; Sun, Maxine ; Fossati, Nicola ; Passoni, Niccolò Maria ; Fiorino, Claudio ; Di Muzio, Nadia ; Karakiewicz, Pierre I ; Rigatti, Patrizio ; Montorsi, Francesco ; Briganti, Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adjuvant</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Grading</topic><topic>Neoplasm recurrence</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Patient Selection</topic><topic>Pelvis</topic><topic>Proportional Hazards Models</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Prostatic neoplasms/surgery</topic><topic>Radiotherapy</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk factors</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdollah, Firas</creatorcontrib><creatorcontrib>Suardi, Nazareno</creatorcontrib><creatorcontrib>Cozzarini, Cesare</creatorcontrib><creatorcontrib>Gallina, Andrea</creatorcontrib><creatorcontrib>Capitanio, Umberto</creatorcontrib><creatorcontrib>Bianchi, Marco</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Fossati, Nicola</creatorcontrib><creatorcontrib>Passoni, Niccolò Maria</creatorcontrib><creatorcontrib>Fiorino, Claudio</creatorcontrib><creatorcontrib>Di Muzio, Nadia</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I</creatorcontrib><creatorcontrib>Rigatti, Patrizio</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdollah, Firas</au><au>Suardi, Nazareno</au><au>Cozzarini, Cesare</au><au>Gallina, Andrea</au><au>Capitanio, Umberto</au><au>Bianchi, Marco</au><au>Sun, Maxine</au><au>Fossati, Nicola</au><au>Passoni, Niccolò Maria</au><au>Fiorino, Claudio</au><au>Di Muzio, Nadia</au><au>Karakiewicz, Pierre I</au><au>Rigatti, Patrizio</au><au>Montorsi, Francesco</au><au>Briganti, Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>63</volume><issue>6</issue><spage>998</spage><epage>1008</epage><pages>998-1008</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><coden>EUURAV</coden><abstract>Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>23122664</pmid><doi>10.1016/j.eururo.2012.10.036</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-2838
ispartof European urology, 2013-06, Vol.63 (6), p.998-1008
issn 0302-2838
1873-7560
language eng
recordid cdi_proquest_miscellaneous_1345513402
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adjuvant
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Cohort Studies
Combined Modality Therapy
Disease-Free Survival
Gynecology. Andrology. Obstetrics
Humans
Lymph Node Excision
Male
Male genital diseases
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Grading
Neoplasm recurrence
Neoplasm Staging
Nephrology. Urinary tract diseases
Patient Selection
Pelvis
Proportional Hazards Models
Prostatectomy
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Prostatic neoplasms/surgery
Radiotherapy
Radiotherapy, Adjuvant
Retrospective Studies
Risk Assessment
Risk factors
Survival Analysis
Treatment Outcome
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Urology
title Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A19%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selecting%20the%20Optimal%20Candidate%20for%20Adjuvant%20Radiotherapy%20After%20Radical%20Prostatectomy%20for%20Prostate%20Cancer:%20A%20Long-term%20Survival%20Analysis&rft.jtitle=European%20urology&rft.au=Abdollah,%20Firas&rft.date=2013-06-01&rft.volume=63&rft.issue=6&rft.spage=998&rft.epage=1008&rft.pages=998-1008&rft.issn=0302-2838&rft.eissn=1873-7560&rft.coden=EUURAV&rft_id=info:doi/10.1016/j.eururo.2012.10.036&rft_dat=%3Cproquest_cross%3E1345513402%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1345513402&rft_id=info:pmid/23122664&rft_els_id=1_s2_0_S0302283812012675&rfr_iscdi=true